AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.11 +1.71%

+$0.04 today

Market cap
$214.74M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.12M

Average 0.32M

Income Statement

Follow revenue through to earnings.

Revenue

$3.57M

FY 2025 · Annual

-86.9% YoY

Operating Income

-$68.86M

FY 2025 · Annual

Net Income

-$70.45M

FY 2025 · Annual

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.94M14.8M27.31M3.57M
Cost of Revenue0054.61M62.57M0
Gross Profit03.94M(39.81M)(35.26M)3.57M
Gross Margin—100.0%-268.9%-129.1%100.0%
Research & Development62.28M60.34M54.61M62.57M56.44M
Selling, General & Admin10.88M9.58M10.58M11.43M11.65M
Operating Expenses79.01M74.78M13.82M17.12M72.44M
Depreciation & Amortization2.41M2.36M2.22M2.16M2.5M
EBITDA(70.01M)(68.03M)(51.83M)(48.62M)(67.75M)
EBITDA Margin—-1728.7%-350.2%-178.0%-1896.2%
Operating Income(79.01M)(70.85M)(53.62M)(52.38M)(68.86M)
Operating Margin—-1800.4%-362.3%-191.8%-1927.3%
Interest Income6.49M69K1.04M3.2M1.87M
Interest Expense581K355K176K133K191K
Other Income / Expenses6.02M107K(599K)1.47M(1.58M)
Income Before Tax(72.99M)(70.74M)(54.22M)(50.91M)(70.45M)
Pre-Tax Margin—-1797.7%-366.3%-186.4%-1971.6%
Income Tax Expense3K13K10K3K0
Net Income(73M)(70.75M)(54.23M)(50.92M)(70.45M)
Net Margin—-1798.0%-366.4%-186.4%-1971.6%
EPS (Basic)(0.97)(0.85)(0.64)(0.51)(0.70)
EPS (Diluted)(0.97)(0.85)(0.64)(0.51)(0.70)
Weighted Avg Shares74.95M83.55M84.69M99.69M100.75M
Weighted Avg Shares (Diluted)74.95M83.55M84.69M99.69M100.75M

ACIU Earnings Waterfall · TTM

NASDAQ:ACIU · Revenue to Net Income

Key Ratios

EPS$-0.66
Gross Margin100.0%
Net Margin-2221.6%
P/E Ratio-3.4
P/S Ratio326.4

Analysis

$3.7M of revenue converted into -$66.2M of net income for the selected period. Gross margin is 100.0% and net margin is -2221.6%, showing how much revenue survives after costs and taxes. EPS is $-0.66, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 4, 2026
3Initial statement of beneficial ownershipOct 9, 2026
3/A3/A filingOct 9, 2026
6-K6-K filingOct 2, 2026
6-K6-K filingSep 23, 2026

How much revenue does ACIU generate?

AC Immune S.A. (ACIU) reported $3.57M of revenue in fiscal 2025.

Is ACIU profitable?

AC Immune S.A. (ACIU) reported -$70.45M of net income, with a net margin of -1971.6%.